Journal
ACS INFECTIOUS DISEASES
Volume 2, Issue 10, Pages 726-733Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acsinfecdis.6b00130
Keywords
influenza A virus; M2 proton channel; M2-S31N inhibitor
Categories
Funding
- University of Arizona
- PhRMA Foundation Research Starter Grant in Pharmacology and Toxicology
- NIH [AI119187]
Ask authors/readers for more resources
Despite the existence of flu vaccines and small molecule antiviral drugs, influenza virus infection remains a public health concern that warrants immediate attention. As resistance to the only orally bioavailable drug, oseltamivir, has been continuously reported, there is a clear need to develop the next-generation of anti-influenza drugs. We chose the influenza A virus M2-S31N mutant proton channel as the drug target to address this need as it is one of the most conserved viral proteins and persist in >95% of currently circulating influenza A viruses. In this study, we report the development of a late-stage diversification strategy for the expeditious synthesis of M2-S31N inhibitors. The channel blockage and antiviral activity of the synthesized compounds were tested in two-electrode voltage clamp assays and antiviral assays, respectively. Several M2-S31N inhibitors were identified to have potent M2-S31N channel blockage and micromolar antiviral efficacy against several M2-S31N-containing influenza A viruses.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available